(Q36018527)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Hepatorenal syndrome: a dreaded complication of end-stage liver disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Andrés Cárdenas

series ordinal

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

460-467

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15667508%20AND%20SRC:MED&resulttype=core&format=json

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Management of cirrhosis and ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Transjugular intrahepatic portosystemic shunt: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

The North American Study for the Treatment of Refractory Ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40952.X